Key result
Cardiac magnetic resonance imaging is evaluated as a noninvasive alternative to endomyocardial biopsy, which has a false negative rate of up to 20%, for detecting acute cardiac allograft rejection.
Why the study?
Endomyocardial biopsy for acute cardiac allograft rejection is invasive, carries complications, misses whole-myocardium assessment, and has false-negative rates up to 20%.
Does cardiac magnetic resonance imaging (CMR) accurately detect acute cardiac allograft rejection in heart transplant patients?
Does cardiac magnetic resonance imaging (CMR) accurately detect acute cardiac allograft rejection in heart transplant patients?
Cardiac magnetic resonance imaging is a promising noninvasive alternative to endomyocardial biopsy for detecting acute cardiac allograft rejection in heart transplant patients.
Supports exploration of CMR to reduce biopsy reliance; leaves open need for prospective validation in transplant rejection monitoring.
The acute cardiac allograft rejection (ACAR) is the leading cause of mortality in patients with heart transplant. Currently, the endomyocardial biopsy (EMB) is considered to be the gold standard in screening for ACAR, which is an invasive procedure with life-threatening complications; however, it does not provide information about the whole myocardium and may give a false negative result in up to 20% of the cases. At the moment, cardiac magnetic resonance imaging (CMR) has become a commonly used diagnostic method. It is known to be a noninvasive and reproducible method for determining cardiac ventricular volumes and muscle mass. It provides tissue-specific information (myocardial edema, necrosis/fibrosis) using different sequences and contrast agents. The purpose of this study is to evaluate the most promising techniques for characterizing myocardial tissue and detecting ACAR using CMR imaging.
No takes yet. Share an insight, caveat, or question.
Kakucs et al. (2022) conducted a review in Acute cardiac allograft rejection. Cardiac magnetic resonance imaging (CMR) vs. Endomyocardial biopsy (EMB) was evaluated on Detection of acute cardiac allograft rejection. Cardiac magnetic resonance imaging is evaluated as a noninvasive alternative to endomyocardial biopsy, which has a false negative rate of up to 20%, for detecting acute cardiac allograft rejection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: